2021 annual financial data
Inhibikase Therapeutics 2021 Operating margin
Direct answer
Operating margin was -476.23%.
Operating income was -14.77M USD and net income was -14.81M USD.
Operating cash flow was -14.3M USD.
Get free Inhibikase Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 3.1M USD
- Operating income
- -14.77M USD
- Net income
- -14.81M USD
- Operating cash flow
- -14.3M USD